

# Qingfeng Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7641433/publications.pdf>

Version: 2024-02-01

102  
papers

4,935  
citations

87888

38  
h-index

91884

69  
g-index

103  
all docs

103  
docs citations

103  
times ranked

6822  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Applications and Perspectives of Humanized Mouse Models. <i>Annual Review of Animal Biosciences</i> , 2022, 10, 395-417.	7.4	18
2	Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinomaâ€“Immune Humanized Mouse Model. <i>Hepatology</i> , 2021, 74, 1395-1410.	7.3	25
3	A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions. <i>Journal of Leukocyte Biology</i> , 2020, 107, 797-807.	3.3	29
4	The Inflammasome Adaptor ASC Intrinsically Limits CD4+ T-Cell Proliferation to Help Maintain Intestinal Homeostasis. <i>Frontiers in Immunology</i> , 2019, 10, 1566.	4.8	15
5	Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms. <i>Translational Oncology</i> , 2019, 12, 987-995.	3.7	32
6	Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. <i>Cells</i> , 2019, 8, 604.	4.1	12
7	Enterovirus A71 Infection Activates Human Immune Responses and Induces Pathological Changes in Humanized Mice. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
8	Humanized Mice as Unique Tools for Human-Specific Studies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 245-266.	2.3	84
9	Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 123-135.	1.9	12
10	Calcineurin-mediated IL-2 production by CD11 <sup>high</sup> MHCII <sup>+</sup> myeloid cells is crucial for intestinal immune homeostasis. <i>Nature Communications</i> , 2018, 9, 1102.	12.8	26
11	Bat-mouse bone marrow chimera: a novel animal model for dissecting the uniqueness of the bat immune system. <i>Scientific Reports</i> , 2018, 8, 4726.	3.3	11
12	Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses. <i>Viruses</i> , 2018, 10, 643.	3.3	19
13	Calcineurin B in CD4+ T Cells Prevents Autoimmune Colitis by Negatively Regulating the JAK/STAT Pathway. <i>Frontiers in Immunology</i> , 2018, 9, 261.	4.8	10
14	A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice. <i>Scientific Reports</i> , 2017, 7, 16642.	3.3	33
15	Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. <i>PLoS ONE</i> , 2017, 12, e0184127.	2.5	16
16	An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 162.	17.0	17
17	Mo1915 Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis. <i>Gastroenterology</i> , 2016, 150, S815.	1.3	0
18	Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. <i>Scientific Reports</i> , 2016, 6, 30802.	3.3	48

#	ARTICLE	IF	CITATIONS
19	Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs. <i>Biomaterials</i> , 2015, 63, 146-157.	11.4	52
20	Solomonsterol A, a Marine Pregnane-X-Receptor Agonist, Attenuates Inflammation and Immune Dysfunction in a Mouse Model of Arthritis. <i>Marine Drugs</i> , 2014, 12, 36-53.	4.6	25
21	In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygenase inhibitors. <i>European Journal of Pharmacology</i> , 2014, 723, 194-201.	3.5	2
22	Dissociation of Intestinal and Hepatic Activities of FXR and LXR $\alpha$ Supports Metabolic Effects of Terminal Ileum Interposition in Rodents. <i>Diabetes</i> , 2013, 62, 3384-3393.	0.6	51
23	Su2132 Dissociation of Activity of Ileal and Liver FXR Mediates Metabolic Effects in a Rodent Model of Bariatric Surgery. <i>Gastroenterology</i> , 2013, 144, S-1090.	1.3	0
24	Su1985 The CCR5 Antagonist Maraviroc Reduces the Potential for Gastric Cancer Dissemination in Rodent Models of Peritoneal Metastasis. <i>Gastroenterology</i> , 2013, 144, S-524.	1.3	0
25	CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. <i>Translational Oncology</i> , 2013, 6, 784-793.	3.7	47
26	Tu2023 A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors. <i>Gastroenterology</i> , 2013, 144, S-907.	1.3	0
27	FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. <i>Pharmacological Research</i> , 2013, 77, 1-10.	7.1	14
28	Epigenetic Modulation by Methionine Deficiency Attenuates the Potential for Gastric Cancer Cell Dissemination. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 39-49.	1.7	14
29	Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by nonsteroidal anti-inflammatory drugs and aspirin in mice. <i>British Journal of Pharmacology</i> , 2013, 168, 225-237.	5.4	17
30	Efficacy of the CCR5 Antagonist Maraviroc in Reducing Early, Ritonavir-Induced Atherogenesis and Advanced Plaque Progression in Mice. <i>Circulation</i> , 2013, 127, 2114-2124.	1.6	114
31	Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2013, 8, e63893.	2.5	89
32	The Bile Acid Sensor FXR Is Required for Immune-Regulatory Activities of TLR-9 in Intestinal Inflammation. <i>PLoS ONE</i> , 2013, 8, e54472.	2.5	82
33	Molecular Determinants of Gastrointestinal and Liver Cancers: Role of Bile Acid Activated Nuclear Receptors. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 625-636.	2.1	2
34	Tu2041 Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE <sup>-/-</sup> Mice. <i>Gastroenterology</i> , 2012, 142, S-909.	1.3	0
35	1009 Epigenetic Modulation of Adhesion and Proliferation Pathways by Methionine Deficiency Attenuates Potential for Dissemination of Gastric Cancer Cells. <i>Gastroenterology</i> , 2012, 142, S-1048.	1.3	0
36	Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C. <i>Molecular BioSystems</i> , 2012, 8, 1412.	2.9	10

#	ARTICLE	IF	CITATIONS
37	4-Methylenesterols from <i>Theonella swinhoei</i> sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. <i>Steroids</i> , 2012, 77, 484-495.	1.8	40
38	1108 Reciprocal Regulation of TLRs and Nuclear Receptors: IRF-7 Dependent Regulation of FXR Mediates Counter-Regulatory Effects of TLR-9 in Colitis. <i>Gastroenterology</i> , 2012, 142, S-200.	1.3	0
39	Tu1920 a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation. <i>Gastroenterology</i> , 2012, 142, S-878.	1.3	0
40	Su1733 The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs. <i>Gastroenterology</i> , 2012, 142, S-491.	1.3	0
41	Tu1417 Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation. <i>Gastroenterology</i> , 2012, 142, S-827.	1.3	0
42	Farnesoid X receptor: from medicinal chemistry to clinical applications. <i>Future Medicinal Chemistry</i> , 2012, 4, 877-891.	2.3	42
43	Plakilactones from the Marine Sponge <i>Plakinastrella mamillaris</i> . Discovery of a New Class of Marine Ligands of Peroxisome Proliferator-Activated Receptor $\beta$ . <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8303-8317.	6.4	47
44	Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis. <i>PLoS ONE</i> , 2012, 7, e30443.	2.5	62
45	Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. <i>FASEB Journal</i> , 2012, 26, 3021-3031.	0.5	48
46	Ritonavir-induced lipodystrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR- $\beta$ -dependent manner. <i>Antiviral Therapy</i> , 2012, 17, 669-678.	1.0	16
47	Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. <i>European Journal of Pharmacology</i> , 2012, 674, 143-152.	3.5	21
48	The HIV Matrix Protein p17 Subverts Nuclear Receptors Expression and Induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes. <i>PLoS ONE</i> , 2012, 7, e35924.	2.5	25
49	VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. <i>PLoS ONE</i> , 2012, 7, e45425.	2.5	90
50	Total Synthesis and Pharmacological Characterization of Solomonsterol A, a Potent Marine Pregnane-X-Receptor Agonist Endowed with Anti-Inflammatory Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4590-4599.	6.4	53
51	the Bile Acid Sensor FXR Induces the Glucocorticoid Receptor in the Liver in a Promoter-Dependent Manner. <i>Gastroenterology</i> , 2011, 140, S-977.	1.3	1
52	Inhibition of NF- $\kappa$ B by a PXR-Dependent Pathway Mediates Counter-regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells. <i>Gastroenterology</i> , 2011, 140, S-639.	1.3	3
53	Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis. <i>Gastroenterology</i> , 2011, 140, S-904.	1.3	0
54	Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs. <i>Gastroenterology</i> , 2011, 140, S-652.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis. <i>Gastroenterology</i> , 2011, 140, S-499.	1.3	0
56	Molecular Determinants of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Model of Peritoneal Gastric Cancer Carcinogenesis. <i>Gastroenterology</i> , 2011, 140, S-1027.	1.3	0
57	Probiotics Modulate Intestinal Expression of Nuclear Receptor and Provide Counter-Regulatory Signals to Inflammation-Driven Adipose Tissue Activation. <i>PLoS ONE</i> , 2011, 6, e22978.	2.5	83
58	The Bile Acids Receptor TGR5 is an Essential Modulator of Intestinal Membrane Permeability and Exerts Anti-Inflammatory Activities in Rodent Model of Colitis. <i>Gastroenterology</i> , 2011, 140, S-26.	1.3	0
59	Mechanistic Role of p38 MAPK in Gastric Cancer Dissemination in a Rodent Model Peritoneal Metastasis. <i>Gastroenterology</i> , 2011, 140, S-1061.	1.3	0
60	The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1522-1531.	3.8	20
61	Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 157-165.	1.9	59
62	The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis. <i>PLoS ONE</i> , 2011, 6, e25637.	2.5	297
63	Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. <i>British Journal of Pharmacology</i> , 2011, 164, 1929-1938.	5.4	32
64	Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. <i>European Journal of Pharmacology</i> , 2011, 665, 29-39.	3.5	51
65	Inhibition of NF- $\kappa$ B by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. <i>European Journal of Pharmacology</i> , 2011, 668, 317-324.	3.5	97
66	SHP-dependent and -independent induction of peroxisome proliferator-activated receptor- $\gamma$ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. <i>Inflammation Research</i> , 2011, 60, 577-587.	4.0	42
67	Hydrogen Sulfide in Gastrointestinal and Liver Physiopathology. <i>Inflammation and Allergy: Drug Targets</i> , 2011, 10, 92-102.	1.8	4
68	Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment. <i>Current Medicinal Chemistry</i> , 2010, 17, 139-159.	2.4	59
69	Hydrogen Sulphide Induces $\frac{1}{4}$ Opioid Receptor-Dependent Analgesia in a Rodent Model of Visceral Pain. <i>Molecular Pain</i> , 2010, 6, 1744-8069-6-36.	2.1	40
70	Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. <i>Biochemical Pharmacology</i> , 2010, 80, 1700-1707.	4.4	86
71	FXR an emerging therapeutic target for the treatment of atherosclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 79-92.	3.6	66
72	The Bile Acid Sensor FXR Protects against Dyslipidemia and Aortic Plaques Development Induced by the HIV Protease Inhibitor Ritonavir in Mice. <i>PLoS ONE</i> , 2010, 5, e13238.	2.5	28

#	ARTICLE	IF	CITATIONS
73	FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. <i>Journal of Lipid Research</i> , 2010, 51, 771-784.	4.2	363
74	M1739 MI3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders. <i>Gastroenterology</i> , 2010, 138, S-409.	1.3	0
75	T1965 Bile Acids Induce Rat PPAR $\alpha$ Gene via Activation of Farnesoid X Receptor.. <i>Gastroenterology</i> , 2010, 138, S-838.	1.3	0
76	542 Farnesoid X Receptor Regulates Glutamate Metabolism: Relevance for Hepatic Encephalopathy. <i>Gastroenterology</i> , 2010, 138, S-791.	1.3	0
77	773 The Bile Acid Sensor FXR Modulates Hydrogen Sulfide Generation in the Gastric Mucosa and Protects Against Injury Caused by Aspirin. <i>Gastroenterology</i> , 2010, 138, S-108.	1.3	0
78	1079 Macrolide Derivatives Devoid of Antibiotic Activity Correct Immune Dysfunction in Rodent Models of Inflammatory Bowel Diseases.. <i>Gastroenterology</i> , 2010, 138, S-157.	1.3	0
79	The bile acid sensor FXR regulates insulin transcription and secretion. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 363-372.	3.8	153
80	Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. <i>Progress in Lipid Research</i> , 2010, 49, 171-185.	11.6	121
81	M1802 Rifaximin is a Human Pregnane X Receptor Activator in Human Colon Epithelial Cells and Regulate Detoxification Pathway. <i>Gastroenterology</i> , 2010, 138, S-422.	1.3	0
82	Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 21783-21788.	7.1	251
83	The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity. <i>Journal of Immunology</i> , 2009, 183, 6251-6261.	0.8	485
84	The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis. <i>Journal of Immunology</i> , 2009, 183, 6657-6666.	0.8	134
85	Antiatherosclerotic effect of farnesoid X receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 296, H272-H281.	3.2	166
86	The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. <i>Biochemical Pharmacology</i> , 2009, 78, 1214-1223.	4.4	74
87	Reciprocal regulation of the bile acid-activated receptor FXR and the interferon- $\gamma$ -STAT-1 pathway in macrophages. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 564-573.	3.8	43
88	Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 570-580.	8.7	295
89	A nitro-arginine derivative of trimebutine (NO $_2$ -Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. <i>Pharmacological Research</i> , 2009, 59, 319-329.	7.1	14
90	16 A Dark Side of FXR Activation in Cholestasis. FXR Is a Negative Regulator of MRP4. <i>Gastroenterology</i> , 2009, 136, A-1.	1.3	0

#	ARTICLE	IF	CITATIONS
91	604 H <sub>2</sub> S Induces Analgesia Is Mediated In Vivo Activation of $\mu$ Opioid Receptor and PI3K/AKT Pathway Activation. <i>Gastroenterology</i> , 2009, 136, A-98.	1.3	0
92	S2070 FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis. <i>Gastroenterology</i> , 2009, 136, A-324.	1.3	0
93	M1735 FXR Activation Reverses Insulin Resistance and Protects Against NASH Development,. <i>Gastroenterology</i> , 2009, 136, A-420-A-421.	1.3	2
94	Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. <i>World Journal of Gastroenterology</i> , 2009, 15, 2097.	3.3	54
95	The methionine connection: Homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. <i>Hepatology</i> , 2008, 47, 659-667.	7.3	63
96	Anti-inflammatory Activity of a New Class of Nitric Oxide Synthase Inhibitors That Release Nitric Oxide. <i>ChemMedChem</i> , 2008, 3, 1580-1588.	3.2	12
97	Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. <i>Anti-Cancer Drugs</i> , 2007, 18, 1081-1091.	1.4	28
98	A Hydrogen Sulfide Releasing Derivative of Mesalamine Exhibits Markedly Enhanced Anti-inflammatory Effects in Experimental Colitis. <i>FASEB Journal</i> , 2007, 21, A131.	0.5	0
99	5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 447-458.	2.5	130
100	Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. <i>FASEB Journal</i> , 2006, 20, 765-767.	0.5	47
101	The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo. <i>Molecular Pharmacology</i> , 2006, 70, 1164-1173.	2.3	145
102	A role for proteinase-activated receptor-1 in inflammatory bowel diseases. <i>Journal of Clinical Investigation</i> , 2006, 116, 2056-2056.	8.2	5